Zuzana Grambalová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zuzana Grambalová has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Dominik Hrabos
Department of Clinical and Molecular Pathology, Palacky University Olomouc and University Hospital Olomouc, Hněvotínská 3, 779 00, Olomouc, Czech Republic.
2 shared publications - Dorota Šebelová
Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, 77900, Czech Republic.
2 shared publications - Jana Zapletalová
Department of Medical Biophysics, Faculty of Medicine and Dentistry Palacký University, Olomouc, Czech Republic
2 shared publications - Katerina Cizkova
Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
2 shared publications - KateřIna Klíčová
Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia
2 shared publications - Kateřina Menšíková
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
2 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Correction: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Open AccessCorrection: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- Open Access
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Open AccessCutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.